新型一氧化氮供体NCX 667在多种动物模型中降低眼压并增强HTM/HSC构建体的常规流出
研究在兔、犬及食蟹猴的多种高眼压模型中评估新型一氧化氮供体NCX 667的降眼压效果,并在生物工程化人小梁网/Schlemm管(HTM/HSC)构建体中探索作用机制。NCX 667在所有模型中呈剂量依赖性降低眼压,1%浓度下各模型最大降幅为-4.1至-12.2 mmHg;在TGFβ2处理的HTM/HSC构建体中浓度依赖性增加流出易度。结果表明其降眼压作用可能源于NO介导的常规流出通路增强。
要点
- NCX 667在兔、犬、猴多种高眼压模型中呈剂量依赖性降低眼压。
- 1% NCX 667在sOHT兔中降幅最大,达-12.2±2.7 mmHg。
- NCX 667增加房水cGMP但不改变视网膜和虹膜/睫状体cGMP。
核心结论
- NCX 667在多种动物模型中产生稳健的降眼压效果。
- HTM/HSC构建体证据提示降眼压可能源于NO介导的常规流出通路增强。
- 房水生成改变和巩膜外静脉压变化等其他机制目前不能排除。
研究设计与样本
- 使用正常眼压新西兰白兔、自发性高眼压Dutch-belted兔、5%高渗盐水诱导暂时性高眼压新西兰白兔、正常眼压Beagle犬和激光诱导高眼压食蟹猴。
- NCX 667或溶媒30 µL以交叉、掩蔽方式滴眼,测量基线及给药后数小时眼压。
- 正常眼压新西兰白兔用于眼组织cGMP测定。
- TGFβ2(2.5 ng/mL,六天)处理的HTM/HSC构建体用于评估流出易度变化。
主要发现
- NCX 667在所有模型中呈稳健且剂量依赖性降眼压。
- 1%浓度最大降眼压幅度:正常眼压犬-4.1±0.6 mmHg,自发性高眼压兔-12.2±2.7 mmHg,暂时性高眼压兔-10.5±2.0 mmHg,正常眼压兔-5.3±0.8 mmHg,高眼压猴-6.6±1.9 mmHg。
- 正常眼压兔中1% NCX 667增加房水cGMP,但不增加视网膜和虹膜/睫状体cGMP。
- TGFβ2处理的HTM/HSC构建体中流出易度:溶媒组0.10±0.06 µL/min/mmHg/mm2,NCX 667组0.30±0.10 µL/min/mmHg/mm2。
临床怎么用
- NCX 667作为NO供体通过增强常规流出通路降眼压,支持其作为青光眼候选药物的进一步开发。
局限性
- 研究仅在动物模型和体外HTM/HSC构建体中进行,尚未在人体验证。
- 房水生成改变和巩膜外静脉压变化等其他机制目前不能排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: NCX 667, a novel nitric oxide (NO) donor with an isomannide core, was characterized for its IOP-lowering ability in animal models of ocular hypertension and glaucoma. Bioengineered human trabecular meshwork/Schlemm's canal (HTM/HSC) constructs were used to explore the mode of action. METHODS: Ocular normotensive New Zealand white (NZW) rabbits (ONT-rabbits), spontaneously ocular hypertensive pigmented Dutch-belted rabbits (sOHT-rabbits), hypertonic saline (5%)-induced transient ocular hypertensive NZW rabbits (tOHT-rabbits), ocular normotensive Beagle dogs (ONT-dogs), and laser-induced ocular hypertensive cynomolgus monkeys (OHT-monkeys) were used. NCX 667 or vehicle (30 µL) was instilled in a crossover, masked fashion and intraocular pressure (IOP) measured before dosing (baseline) and for several hours thereafter. The ONT-rabbits were used for cyclic guanosine monophosphate (cGMP) determination in ocular tissues after ocular dosing with NCX 667. Transforming growth factor-beta2 (TGFβ2) (2.5 ng/mL, six days)-treated HTM/HSC constructs were used to address changes in outflow facility. RESULTS: NCX 667 resulted in robust and dose-dependent IOP decrease in all models used. Maximal IOP-lowering efficacy at 1% was -4.1 ± 0.6, -12.2 ± 2.7, -10.5 ± 2.0, -5.3 ± 0.8, and -6.6 ± 1.9 mmHg, respectively, in ONT-dogs, sOHT-rabbits, tOHT-rabbits, ONT-rabbits, and OHT-monkeys. In ONT-rabbits NCX 667 (1%) increased cGMP in aqueous humor (AH) but not in retina and iris/ciliary body. NCX 667 concentration-dependently increased outflow facility in TGFβ2-treated HTM/HSC constructs (outflow facility, 0.10 ± 0.06 and 0.30 ± 0.10 µL/min/mmHg/mm2, respectively, in vehicle- and NCX 667-treated constructs). CONCLUSIONS: NCX 667 leads to robust IOP lowering in several animal models. Evidence in HTM/HSC constructs indicate that the IOP reduction likely results from NO-mediated increase of the conventional outflow pathway. Other mechanisms including changes in AH production and episcleral vein pressure may not be excluded at this time.
引用
- Bastia E, Toris CB, Brambilla S, et al. NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs. Invest Ophthalmol Vis Sci. 2021. PMID: 33704360. doi:10.1167/iovs.62.3.17
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。